Skip to main content

A Multicenter, Open-Label Study Evaluating the Long-Term Safety, and Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years

Clinical Trial Grant
Duke Scholars

Administered By

School of Medicine

Awarded By

Teva Branded Pharmaceutical Products R&D, Inc

Start Date

January 4, 2022

End Date

January 31, 2027
 

Administered By

School of Medicine

Awarded By

Teva Branded Pharmaceutical Products R&D, Inc

Start Date

January 4, 2022

End Date

January 31, 2027